Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Torti

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Infection|August 12, 2009
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort studyS Di Giambenedetto, C Torti, M Prosperi, et al.
International Journal of Antimicrobial Agents|April 23, 2023
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19A Russo, A Bruni, S Gullì, et al.
The Journal of Antimicrobial Chemotherapy|October 15, 2025
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatmentsE Matteini, C Pinnetti, F Frondizi, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovirK Theys, J Vercauteren, J Snoeck, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 17, 2011
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapyC Torti, M Prosperi, D Motta, et al.
Infection|May 28, 2009
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER CohortsC Torti, G Lapadula, A Antinori, et al.
Infection|May 6, 2008
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort studyL Sighinolfi, C Torti, C Zeni, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 28, 2012
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010M Colafigli, C Torti, E M Trecarichi, et al.
HIV Medicine|June 23, 2018
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016B Rossetti, S Di Giambenedetto, C Torti, et al.
Mucosal Immunology|April 29, 2011
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trialA Gori, G Rizzardini, B Van't Land, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Infection|August 12, 2009
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort studyS Di Giambenedetto, C Torti, M Prosperi, et al.
International Journal of Antimicrobial Agents|April 23, 2023
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19A Russo, A Bruni, S Gullì, et al.
The Journal of Antimicrobial Chemotherapy|October 15, 2025
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatmentsE Matteini, C Pinnetti, F Frondizi, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovirK Theys, J Vercauteren, J Snoeck, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 17, 2011
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapyC Torti, M Prosperi, D Motta, et al.
Infection|May 28, 2009
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER CohortsC Torti, G Lapadula, A Antinori, et al.
Infection|May 6, 2008
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort studyL Sighinolfi, C Torti, C Zeni, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 28, 2012
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010M Colafigli, C Torti, E M Trecarichi, et al.
HIV Medicine|June 23, 2018
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016B Rossetti, S Di Giambenedetto, C Torti, et al.
Mucosal Immunology|April 29, 2011
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trialA Gori, G Rizzardini, B Van't Land, et al.
Pageof 9